Norinchukin Bank The Trims Holdings in Humana Inc. (NYSE:HUM)

Norinchukin Bank The lessened its holdings in shares of Humana Inc. (NYSE:HUM) by 1.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,720 shares of the insurance provider’s stock after selling 111 shares during the period. Norinchukin Bank The’s holdings in Humana were worth $4,494,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Wade G W & Inc. boosted its position in Humana by 3.1% during the 1st quarter. Wade G W & Inc. now owns 775 shares of the insurance provider’s stock valued at $325,000 after acquiring an additional 23 shares in the last quarter. Lindbrook Capital LLC boosted its position in Humana by 12.1% during the 1st quarter. Lindbrook Capital LLC now owns 231 shares of the insurance provider’s stock valued at $97,000 after acquiring an additional 25 shares in the last quarter. AdvisorNet Financial Inc boosted its position in Humana by 54.5% during the 1st quarter. AdvisorNet Financial Inc now owns 85 shares of the insurance provider’s stock valued at $36,000 after acquiring an additional 30 shares in the last quarter. Wedbush Securities Inc. boosted its position in Humana by 3.8% during the 1st quarter. Wedbush Securities Inc. now owns 882 shares of the insurance provider’s stock valued at $370,000 after acquiring an additional 32 shares in the last quarter. Finally, Parallel Advisors LLC boosted its position in Humana by 3.0% during the 1st quarter. Parallel Advisors LLC now owns 1,125 shares of the insurance provider’s stock valued at $472,000 after acquiring an additional 33 shares in the last quarter. 92.11% of the stock is currently owned by institutional investors and hedge funds.

Shares of HUM opened at $420.96 on Friday. The stock has a market cap of $54.31 billion, a price-to-earnings ratio of 14.97, a PEG ratio of 1.46 and a beta of 0.88. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.67 and a current ratio of 1.67. The company’s fifty day moving average is $437.99. Humana Inc. has a 1-year low of $365.06 and a 1-year high of $475.44.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, April 28th. The insurance provider reported $7.67 earnings per share for the quarter, beating analysts’ consensus estimates of $7.21 by $0.46. The business had revenue of $20.67 billion during the quarter, compared to analyst estimates of $20.42 billion. Humana had a net margin of 4.72% and a return on equity of 19.08%. The company’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same period in the previous year, the business earned $5.40 EPS. Research analysts expect that Humana Inc. will post 21.64 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, July 30th. Shareholders of record on Wednesday, June 30th will be paid a dividend of $0.70 per share. The ex-dividend date is Tuesday, June 29th. This represents a $2.80 dividend on an annualized basis and a yield of 0.67%. Humana’s dividend payout ratio is presently 14.93%.

A number of brokerages have recently commented on HUM. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell boosted their price target on Humana from $496.00 to $510.00 and gave the stock a “buy” rating in a research report on Thursday, April 29th. Zacks Investment Research cut Humana from a “hold” rating to a “sell” rating and set a $447.00 price target on the stock. in a research report on Tuesday, March 30th. Oppenheimer boosted their price target on Humana from $460.00 to $480.00 and gave the stock an “outperform” rating in a research report on Thursday, April 29th. Citigroup boosted their price target on Humana from $496.00 to $510.00 in a research report on Thursday, April 29th. Finally, Mizuho boosted their price target on Humana from $462.00 to $480.00 and gave the stock a “buy” rating in a research report on Thursday, April 29th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company’s stock. Humana currently has an average rating of “Buy” and an average price target of $469.00.

In other news, insider Timothy Alan Wheatley sold 8,508 shares of the company’s stock in a transaction on Monday, May 3rd. The stock was sold at an average price of $450.59, for a total value of $3,833,619.72. Following the completion of the sale, the insider now directly owns 11,494 shares in the company, valued at approximately $5,179,081.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Christopher H. Hunter sold 5,156 shares of the company’s stock in a transaction on Thursday, April 29th. The stock was sold at an average price of $443.76, for a total value of $2,288,026.56. Following the completion of the sale, the insider now owns 8,653 shares of the company’s stock, valued at $3,839,855.28. The disclosure for this sale can be found here. Corporate insiders own 0.40% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Article: How to Use the MarketBeat Retirement Calculator

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.